Form 4: Pfizer Executive Aamir Malik Modifies Stock Appreciation Rights
SEC Form 4
Executive Vice President Aamir Malik modifies stock appreciation rights (TSRUs) to extend their vesting and settlement dates by two years.
Summary
- Aamir Malik, an Executive Vice President at Pfizer Inc., modified his stock appreciation rights (TSRUs) on September 12, 2024.
- The modification extends the vesting and settlement dates of certain outstanding TSRUs by two years.
- This action was taken pursuant to a one-time offer by Pfizer to modify eligible TSRUs, as detailed in the Schedule TO filed on August 12, 2024.
- Malik modified 103,320 TSRUs with an original expiration date of February 23, 2028, extending it to February 23, 2030.
- He also modified 84,529 TSRUs with an original expiration date of February 24, 2027, extending it to February 24, 2029.
- The grant price and the number of shares underlying the modified TSRUs remain unchanged.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't convey strong positive or negative sentiment.
Future Outlook
The document does not contain specific forward-looking statements beyond the extension of the TSRU vesting and settlement dates.
Industry Context
This filing reflects a common practice of companies using stock appreciation rights as part of executive compensation packages to align management's interests with those of shareholders. The modification offer suggests a strategic decision by Pfizer to potentially retain executives or incentivize long-term performance.
Comparison to Industry Standards
- Stock appreciation rights are a common component of executive compensation packages in the pharmaceutical industry, used by companies like Johnson & Johnson, Merck, and AbbVie.
- The terms and conditions of these TSRUs, including vesting schedules and performance metrics, are typically benchmarked against industry peers to ensure competitiveness and alignment with shareholder value creation.
- Modifications to existing TSRUs, such as the extension of vesting dates, are less common but can be used as a tool for retention or to adjust incentives in response to changing market conditions or company strategy.
Stakeholder Impact
- The modification of TSRUs could potentially impact shareholder value if it better aligns executive incentives with long-term company performance.
- The modification of TSRUs could potentially impact employee morale if it is seen as a positive change to their compensation.
Key Dates
| Date | Description |
|---|---|
| August 12, 2024 | Pfizer filed the Tender Offer Statement on Schedule TO detailing the one-time offer to modify Eligible TSRUs. |
| September 12, 2024 | Aamir Malik modified his stock appreciation rights (TSRUs). |
| September 16, 2024 | Date of the Form 4 filing. |
| February 23, 2028 | Original expiration date of 103,320 TSRUs before modification. |
| February 23, 2030 | New expiration date of 103,320 TSRUs after modification. |
| February 24, 2027 | Original expiration date of 84,529 TSRUs before modification. |
| February 24, 2029 | New expiration date of 84,529 TSRUs after modification. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.